Insights into nanomedicine for immunotherapeutics in squamous cell carcinoma of the head and neck

Qiang Xu, Meiyu Fang, Jing Zhu, Haoru Dong, Jun Cao, Lin Yan, Fransisca Leonard, Felix Oppel, Holger Sudhoff, Andreas M. Kaufmann, Andreas E. Albers, Xu Qian

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Immunotherapies such as immune checkpoint blockade benefit only a portion of patients with head and neck squamous cell carcinoma. The multidisciplinary field of nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer immunotherapy and to turn non-responders into responders. Various methods have been developed to deliver therapeutic agents that can overcome bio-barriers, improve therapeutic delivery into the tumor and lymphoid tissues and reduce adverse effects in normal tissues. Additional modification strategies also have been employed to improve targeting and boost cytotoxic T cell-based immune responses. Here, we review the state-of-the-art use of nanotechnologies in the laboratory, in advanced preclinical phases as well as those running through clinical trials assessing their advantages and challenges.

Original languageEnglish (US)
Pages (from-to)2506-2517
Number of pages12
JournalInternational Journal of Biological Sciences
Issue number14
StatePublished - Jul 19 2020


  • Cancer immunotherapy
  • Drug delivery
  • Head and neck squamous cell carcinoma, human papillomavirus
  • Nanotherapeutics
  • Nanovaccine

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Insights into nanomedicine for immunotherapeutics in squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this